At Least Three Ring Hetero Atoms In The Bicyclo Ring System Patents (Class 548/360.5)
  • Patent number: 6867202
    Abstract: This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and th compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: March 15, 2005
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, Charles Kwok-Fung Chiu, Lydia Codetta Pan, Bruce Allen Lefker, Judith Lee Treadway, Michael Paul Zawistoski
  • Patent number: 6783557
    Abstract: The invention concerns novel pyrazolo[1,5-a]pyrimidines comprising at least a cationic group Z, Z being selected among quaternized aliphatic chains, aliphatic chains comprising at least a quaternized cycle, and their use as oxidation base for dyeing keratin fibers, the dyeing compositions containing them, and the oxidation dyeing methods using them.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: August 31, 2004
    Assignee: L'Oreal S.A.
    Inventors: Eric Terranova, Aziz Fadli, Alain Lagrange
  • Patent number: 6770664
    Abstract: Bicyclic heterocyclic substituted phenyl oxazolidinone compounds of the formula: wherein Y is a radical of Formulae II or III: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: August 3, 2004
    Inventors: Steven D. Paget, Dennis J. Hlasta
  • Patent number: 6706889
    Abstract: Dinitropyrazolopyrazole-amine salts are used as burn modifier ingredients in gun propellant compositions.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: March 16, 2004
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Alfred G. Stern, Jesse S. Moran, R. Jason Jouet, Michael E. Sitzman, Philip F. Pagoria, Gregory S. Lee
  • Patent number: 6630487
    Abstract: This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: October 7, 2003
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, Charles Kwok-Fung Chiu, Lydia Codetta Pan, Bruce Allen Lefker, Judith Lee Treadway, Michael Paul Zawistoski
  • Publication number: 20030100554
    Abstract: This invention relates to pyrazole derivatives of formula (I) 1
    Type: Application
    Filed: April 5, 2002
    Publication date: May 29, 2003
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 6559174
    Abstract: Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: May 6, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Linus S. Lin, Shrenik K. Shah, Linda L. Chang, William K. Hagmann, Richard A. Mumford
  • Publication number: 20030069278
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: April 19, 2002
    Publication date: April 10, 2003
    Applicant: Wyeth
    Inventors: Ping Zhou, Boyd Lynn Harrison, Yanfang Li
  • Publication number: 20030023082
    Abstract: The present invention relates to bicyclic compounds wherein one of the cyclic moieties is a 16-membered macrocycle and to methods for making and using these compounds.
    Type: Application
    Filed: May 13, 2002
    Publication date: January 30, 2003
    Inventors: Gary Ashley, Brian Metcalf
  • Patent number: 6448263
    Abstract: This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: September 10, 2002
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, Charles Kwok-Fung Chiu, Lydia Codetta Pan, Bruce Allen Lefker, Judith Lee Treadway, Michael Paul Zawistoski
  • Patent number: 6358885
    Abstract: This invention relates to certain phenylheterocyclic compounds, herbicidal compositions thereof and a method for their use as general and selective preemergent or postemergent herbicides or plant growth regulants.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: March 19, 2002
    Assignees: Mississippi State University, Research Technology Corporation Mississippi State
    Inventors: Thomas P. Selby, Thomas M. Stevenson
  • Patent number: 6303543
    Abstract: A compound represented by the formula (I) or its salt and herbicidal and desiccant use thereof: wherein X, Y are independently hydrogen, halogen, cyano, nito, or (C1-6)haloalkyl; Z is oxygen or sulfur; and
    Type: Grant
    Filed: May 15, 2000
    Date of Patent: October 16, 2001
    Assignee: Ishihara Sangyo Kaisha, Ltd.
    Inventors: David A. Pulman, Bai-Ping Ying, Shao-Yong Wu, Sandeep Gupta, Masamitsu Tsukamoto, Takahiro Haga
  • Patent number: 6278000
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: August 21, 2001
    Assignee: Pfizer Inc.
    Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
  • Patent number: 6242609
    Abstract: A method for manufacturing a color coupler used in a silver halide photographic light-sensitive material using an ammonium trihalide. Said method for manufacturing the color coupler comprising the following step: a step for halogenating a coupling position of a four equivalent coupler using a halogenating agent, wherein said halogenating agent is said ammonium trihalide.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: June 5, 2001
    Assignee: Konica Corporation
    Inventor: Fumio Ishii